The executive director of the British Columbia Securities Commission has halted trading in Noveris Health Sciences Inc. securities, citing unusual and unexplained fluctuations in trading volume and market price and concerns about orderly trading. The halt also follows staff concerns about potential inconsistencies between the company’s March 11 offering document and its most recent financial statements, as well as allegedly untrue and misleading promotional materials about the company. Noveris’s share price on the Canadian Securities Exchange rose 423% from CAD 0.42 to CAD 2.20 between 13 March and 19 March, while average daily trading volume between 16 March and 19 March was nearly 200,000 shares versus a prior 30-day average of about 6,000 shares. Noveris also trades on the Frankfurt Stock Exchange and is quoted on U.S. over-the-counter markets. Trading is halted until 16 April 2026. The BCSC noted that halt trade orders can last no more than 15 business days, although they can be extended.
British Columbia Securities Commission 2026-03-25
British Columbia Securities Commission halts trading in Noveris Health Sciences until 16 April 2026 amid unexplained price and volume moves
The British Columbia Securities Commission has halted trading in Noveris Health Sciences Inc. securities due to unexplained fluctuations in trading volume and market price, and concerns over potential inconsistencies in the company's offering document and financial statements. Noveris's share price surged 423% on the Canadian Securities Exchange, with trading volumes significantly exceeding the prior average. The halt is in effect until 16 April 2026, with the possibility of extension.